Hypermethylation of <i>SOX1</i> and <i>HOXA9</i> Genes Is Associated with Clinicopathologic Characteristics of Non-Small Cell Lung Cancer Patients
DNA methylation changes, especially hypermethylation of <i>SOX1</i> and HOXA9, may serve as biomarkers for diagnosis and prognosis in non-small cell lung carcinoma (NSCLC). This study analyzed the methylation status of <i>SOX1</i> and <i>HOXA9</i> in 63 primary NS...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/47/6/397 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | DNA methylation changes, especially hypermethylation of <i>SOX1</i> and HOXA9, may serve as biomarkers for diagnosis and prognosis in non-small cell lung carcinoma (NSCLC). This study analyzed the methylation status of <i>SOX1</i> and <i>HOXA9</i> in 63 primary NSCLC tumor samples, corresponding normal lung tissues, and circulating blood, using bisulfite pyrosequencing. The relationship between methylation patterns and clinicopathologic features was also explored. <i>SOX1</i> and <i>HOXA9</i> promoter methylation levels were significantly higher in tumor tissues compared to normal lung tissues and blood samples. Histological subtypes influenced methylation patterns, with squamous cell carcinomas (SCC) showing higher hypermethylation rates at both loci compared to other NSCLC subtypes. <i>HOXA9</i> hypermethylation was associated with advanced tumor stage (stages II and III). Gender and smoking status did not correlate with methylation status. These findings highlight the cancer-specific nature of <i>SOX1</i> and HOXA9 hypermethylation in NSCLC. Further investigation into demographic and molecular factors influencing methylation could enhance the clinical utility of <i>SOX1</i> and <i>HOXA9</i> in NSCLC diagnosis and management. |
|---|---|
| ISSN: | 1467-3037 1467-3045 |